FINAL EXAM DECEMBER 2012 NATIONAL BOARD OF EXAMINATIONS

HEMATOLOGY

PAPER - I

Time : 3 hours Max. Marks : 100 HEMAT/D/12/48/I

Attempt all questions in order. Each question carries 10 marks.

Write short notes on:

1.	Principle of stem cell transplantation.	10
2.	Diagnosis and management of iron overload syndrome.	10
3.	Micro RNAs in hematological neoplasia.	10
4.	Fibrinolytic inhibitors and thrombophilia.	10
5.	Platelet refractoriness: Causes and mechanisms.	10
6.	Role of flow cytometry in detection of minimal residual disease in acute lymphoblastic leukemia.	10
7.	Gene therapy in hematological disorders.	10
8.	2008 WHO classification of Myelodysplastic Syndrome (MDS).	10
9.	Blood components.	10
10.	T regulatory cells in hematological malignancies.	10

FINAL EXAM DECEMBER 2012 NATIONAL BOARD OF EXAMINATIONS

HEMATOLOGY

PAPER - II

Time : 3 hours

HEMAT/D/12/48/II

Max. Marks: 100

Attempt all questions in order. Each question carries 10 marks.

Write short notes on:

1.	Diagnosis & management of Langerhan cell histiocytosis.	10
2.	Risk stratification in Myelodysplastic Syndrome (MDS).	10
3.	Role of D-dimers in diagnosis and management of deep vein thrombosis.	10
4.	Management of a 45 year old patient with pure red cell aplasia.	10
5.	Hematogones and their significance.	10
6.	Gleevac resistance in CML and its causes.	10
7.	Benign monoclonal lymphocytosis.	10
8.	Managing Factor VIII inhibitors.	10
9.	Diagnosis and management of thrombotic thrombocytopenic purpura.	10
10.	Iron refractory iron deficiency anemia.	10

FINAL EXAM DECEMBER 2012 NATIONAL BOARD OF EXAMINATIONS

HEMATOLOGY PAPER – III

Time

: 3 hours

HEMAT/D/12/48/III

Max. Marks: 100

Attempt all questions in order. Each question carries 10 marks.

Write short notes on:

1.	How will you diagnose and manage a 25 year old female with 9 abortions?	10
2.	Use of demethylating agents in treatment of Myelodysplastic Syndrome (MDS).	10
3.	Micro-environment of bone marrow.	10
4.	Guidelines in diagnosis and management of ITP in India.	10
5.	Use of Flow Cytometry for PNH diagnosis.	10
6.	Prognostic markers in cytogenetically normal AML & their implications in therapy.	10
7.	Newer prognostic markers in multiple myeloma.	10
8.	Diagnosis and management of large granular lymphocytic leukemia.	10
9.	Diagnosis and management of HbE thalassemia.	10
10.	Newer anticoagulants.	10
